Hims & Hers Health (NYSE:HIMS) Insider Sells $136,511.01 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 5,529 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the sale, the insider owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This represents a 38.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Hims & Hers Health Stock Performance

HIMS traded down $1.75 on Wednesday, reaching $23.23. The company had a trading volume of 34,826,246 shares, compared to its average volume of 35,648,238. The stock has a market cap of $5.30 billion, a P/E ratio of 45.55, a P/E/G ratio of 2.42 and a beta of 2.55. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company’s fifty day moving average is $23.43 and its 200 day moving average is $37.08.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same period last year, the business posted $0.11 earnings per share. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Partnership with Novo Nordisk gives HIMS direct telehealth access to Ozempic and Wegovy, expanding its addressable market for weight‑loss/diabetes prescriptions and enabling a pre‑launch waitlist that could drive near‑term patient acquisition. Hims & Hers opens up pre-launch waitlist for Ozempic and Wegovy
• Positive Sentiment: The deal also resolves public friction between the companies and broadens branded GLP‑1 distribution via telehealth — a strategic win that supports HIMS’s growth narrative if conversion and pricing hold. Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus
• Neutral Sentiment: Sell‑side and value commentators are highlighting HIMS as a potential long‑term beneficiary of GLP‑1 demand; these bullish previews could help sentiment but depend on execution and margin outcomes. Leerink Partners Forecasts Strong Price Appreciation for Hims & Hers Health Value Investing With Raul Shah
• Negative Sentiment: Major insider selling: COO Michael Chi sold 97,289 shares (~$2.4M) and other insiders (Soleil Boughton, Irene Becklund) also trimmed positions on Mar 17 — large insider sales can be read as a negative signal by investors even if not uncommon. SEC filings: Michael Chi Form 4 Soleil Boughton Form 4 Irene Becklund Form 4
• Negative Sentiment: GLP‑1 pricing competition is heating up (HSBC and other analysts): faster price cuts or competitive pressure from Lilly and copycat drugs could compress margins and reduce the revenue upside of greater volume. Health Care Roundup: Market Talk

Analysts Set New Price Targets

A number of research analysts have commented on the company. BTIG Research lowered Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, March 10th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research report on Monday, March 9th. Finally, Bank of America upgraded shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and lifted their price objective for the stock from $12.50 to $23.00 in a research note on Tuesday, March 10th. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $31.29.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth $28,000. Binnacle Investments Inc acquired a new stake in Hims & Hers Health during the third quarter worth about $28,000. Virtus Advisers LLC bought a new position in Hims & Hers Health in the 2nd quarter valued at about $26,000. Hilltop National Bank acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at approximately $35,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Hims & Hers Health by 408.2% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after acquiring an additional 600 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.